key: cord-1038538-g0l6hh55 authors: Pal, Rimesh; Bhadada, Sanjay K. title: Reply to Comment on “Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?” date: 2020-05-06 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108192 sha: dbf4fa93e965ca89e2123a49362cb649cf445ede doc_id: 1038538 cord_uid: g0l6hh55 nan We went through the comment by Cure et al. in rebuttal to our article entitled "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?" (1) Although it is interesting, certain clarifications are needed. Firstly, the authors do agree that insulin reduces the activity of ADAM-17, metalloproteinase that cleaves ACE2 (2, 3) . This should, in turn, increase the expression of ACE2. On the contrary, Cure et al. state that ACE2 levels are reduced with insulin. This disparity needs clarification. Secondly, we agree with the authors that activation of NHE by insulin can lead to intracellular alkalization and inhibit binding and entry of SARS-CoV-2. However, NHE1 activity of erythrocytes has been found to be insulin-resistant in obese subjects (4) . Interestingly, NHE1 is also predominantly expressed in lungs and might be resistant to the action of insulin in people with T2DM. Moreover, activation of NHE1 in the pulmonary arterial has been implicated in the pathogenesis of pulmonary arterial hypertension (5) . This would be undesirable in a patient with COVID-19 and acute respiratory distress syndrome. Thirdly, the original commentary by us was intended towards people with diabetes mellitus (DM) at risk for developing COVID-19 and not towards those already diagnosed with COVID-19. However, much of the comments put forward by Cure et al. cater to people with DM already having COVID-19. As in any patient with severe infection/sepsis/hypoxia, use of metformin in COVID-19 does theoretically increase the risk of lactic acidosis (6) . Notwithstanding this fact, metformin use in patients with severe septic shock has been found to significantly lower in-hospital mortality as compared to non-users (7) . Finally, the discussion on dapagliflozin is also controversial. By inhibiting NHE, dapagliflozin should theoretically result in intracellular acidosis. Thus, activation of NHE by insulin and subsequent rise in intracellular pH will be counteracted by inhibition of NHE by dapagliflozin when both drugs are used in combination. Moreover, patients on dapagliflozin will be at a higher risk of dehydration and acute kidney injury amid the already increased insensible water loss precipitated by fever and tachypnea (8) . Lastly, acute illness happens to be the most common precipitating factor for euglycemic diabetic ketoacidosis (DKA) in patients on SGLT2 inhibitors (9). Moreover, SARS-CoV-2, per se may aggravate pancreatic β-cell damage and precipitate DKA (10) . Thus, in the absence of robust data, we would be highly skeptical and advice against the use of dapagliflozin in diabetic patients with COVID-19. Insulin however remains a good choice for in-hospital patients; however, in the absence of in-clinic visits, it might be difficult to counsel diabetic patients in community about insulin usage amid the ongoing pandemic. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice The Effect of Insulin on Na + -H + Antiport Activity of Obese and Normal Subjects Erythrocytes Na + /H + Exchange and Hypoxic Pulmonary Hypertension The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes Lactic acidosis and severe septic shock in metformin users: a cohort study Practical recommendations for the management of diabetes in patients with COVID-19 Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus